We serve Chemical Name:2-(1-Fluorocyclopentyl)-2-hydroxyacetonitrile CAS:79205-55-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(1-Fluorocyclopentyl)-2-hydroxyacetonitrile
CAS.NO:79205-55-3
Synonyms:(1-fluoro-cyclopentyl)-hydroxy-acetonitrile
Molecular Formula:C7H10FNO
Molecular Weight:143.15900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:44.02000
Exact Mass:143.07500
LogP:1.15318
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (1-fluoro-cyclopentyl)-hydroxy-acetonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(1-fluoro-cyclopentyl)-hydroxy-acetonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1-fluoro-cyclopentyl)-hydroxy-acetonitrile Use and application,(1-fluoro-cyclopentyl)-hydroxy-acetonitrile technical grade,usp/ep/jp grade.
Related News: The review by EMA’s safety committee (PRAC) supported by experts from the Committee for Advanced Therapies (CAT) found that the viral vector was unlikely to be the cause. (2R,5aR,6aR,7S,8S,9R,10S,10aR,11aS)-5a,8,10-trihydroxy-2-methyl-7,9-bis(methylamino)-2,3,4,6a,7,8,9,10,10a,11a-decahydrobenzo[1,2][1,4]dioxino[3,4-c]oxepin-5-one manufacturers Earlier this month, the drugmaker lifted a voluntary EU marketing hold on Zynteglo for beta thalassemia, after a patient death in one of the drugmaker’s other products, LentiGlobin, halted clinical studies. (1S)-N-benzyloxycarbonyl-1-(3-(benzyloxy)-5-methoxy-4-methylphenyl)-2-((2-methoxyethoxy)methoxy)ethylamine suppliers A CDMO must have bolt-on capabilities with efficient chemistry which translates into adding new capabilities that the specific molecule development may require quickly. 8-[(2R,3S)-3-heptyloxiran-2-yl]-1-methoxyocta-4,6-diyn-3-one vendor & factory A CDMO must have bolt-on capabilities with efficient chemistry which translates into adding new capabilities that the specific molecule development may require quickly. ,However, to leverage these benefits, it is vital that biocatalytic processes be evaluated as early in the drug development life cycle as possible. Fortunately, the growing availability of diverse kits of enzyme classes can facilitate this process, allowing researchers to screen enzymes/biocatalysts in much the same way as traditional screening of metal catalysts is performed.
